Head and neck cancers display notable heterogeneity in their immune cell infiltrates, which reflect intricate spatial arrangements and dynamic networks of ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and ...

Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in developing countries, where access to early diagnosis, comprehensive care, and research infrastructure is ...

Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) - Topline data expected by the end of Q1 2028 as per planPhase 1 data from TG4050 in head and neck cancer published ...

Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...

Head and neck cancer symptoms vary by tumor location, often presenting as a neck lump or voice changes. Smoking and HPV are major risk factors; cessation and vaccination are crucial preventive ...

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and ...